Quality of care of patients with type-2 diabetes in Galicia (NW Spain) [OBTEDIGA project

International Journal of Clinical Practice

Volumn 65, Issue 10, 2011, Pages 1067-1075

  Vidal Pardo, J I ^a   Perez Castro T R ^b   Lopez Ulvarez X L ^c   Garcia Soidan F J ^d   Santiago Perez M I ^e   Muniz J ^b  

^a Hospital Universitario Lucus Augusti   (Spain)

^b UNIVERSITY OF A CORUÑA   (Spain)

^c Centro de Saude Marinamansa A Cuna   (Spain)

^d Centro de Salud de Porrino   (Spain)

^e ODDS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL CIRCUMFERENCE; ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL COMPETENCE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; EYE EXAMINATION; FEMALE; FOOT EXAMINATION; GENERAL PRACTITIONER; GOOD CLINICAL PRACTICE; HEALTH CARE QUALITY; HEALTH CARE SURVEY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL EXAMINATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RESIDENCY EDUCATION; SMOKING; SPAIN; WAIST CIRCUMFERENCE;

AGED; ALBUMINURIA; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIET; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PHYSICAL EXAMINATION; QUALITY OF HEALTH CARE; SPAIN;

EID: 80052970988     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02739.x     Document Type: Article

References (46)

1. Goday A,. [Epidemiology of diabetes and its non-coronary complications. Rev Esp Cardiol 2002; 55: 657-70. (Pubitemid 34752769)
2. Massi-Benedetti M, Board C-A,. The cost of diabetes type II in Europe: the CODE-2 study. Diabetologia 2002; 45: S1-4. (Pubitemid 34762207)
3. Wild S, Roglic G, Green A, et al., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53. (Pubitemid 38579764)
4. International Diabetes Federation. IDF Diabetes Atlas, 4th edn. Brussels, Belgium: International Diabetes Federation, 2009.
5. Catalá Bauset M, Girbés Borrás J, Lluch Verdú I, et al., Estudio de prevalencia de diabetes en la Comunidad Valenciana. Av Diabetol 2006; 22 (Suppl.): 13.
6. Castell C, Tresserras R, Serra J, et al., Prevalence of diabetes in Catalonia (Spain): an oral glucose tolerance test-based population study. Diabetes Res Clin Pract 1999; 43: 33-40. (Pubitemid 29096409)
7. Soriguer-Escofet F, Esteva I, Rojo-Martinez G, et al., Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain. Diabetes Res Clin Pract 2002; 56: 213-20. (Pubitemid 34269662)
8. Valdés S, Botas P, Delgado E, Díaz Cadõrniga F,. Mortality risk in spanish adults with diagnosed diabetes, undiagnosed diabetes or pre-diabetes. The Asturias study 1998-2004. Rev Esp Cardiol 2009; 62: 528-34.
9. Muñiz J, Cordido F, Rodriguez IL, Beiras AC,. Effect of the application of the new diagnostic criteria of diabetes mellitus in the prevalence estimates and diagnostic level in the general population. European J Publ Health 1999; 9: 149-51. (Pubitemid 29274784)
10. Muñiz J, Hervada J, Juane R, et al., Prevalence of diabetes mellitus in the population aged 40-69 years in Galicia, northwest Spain. Diabetes Res Clin Pract 1995; 30: 137-42. (Pubitemid 26076842)
11. Nathan D, Cleary P, Backlund J, et al., Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53. (Pubitemid 41817713)
12. Holman R, Paul S, Bethel M, et al., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
13. Gerstein H, Miller M, Byington R, et al., Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59. (Pubitemid 351831356)
14. Duckworth W, Abraira C, Moritz T, et al., Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39.
15. Patel A, MacMahon S, Chalmers J, et al., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72. (Pubitemid 351831357)
16. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2007; 30: S4-41.
17. Orozco-Beltrán D, Gil-Guillen V, Quirce F, et al., Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract 2007; 61: 909-15. (Pubitemid 46745231)
18. Hibbard J,. What can we say about the impact of public reporting? Inconsistent execution yields variable results. Ann Intern Med 2008; 148: 160-1. (Pubitemid 351651558)
19. Plan de Saúde 2006-2010. Santiago de Compostela: Xunta de Galicia. Consellería de Sanidade. Direcciõn Xeral de Aseguramento e Planificaciõn Sanitaria 2006: 73-86.
20. Wingard D, Barrett-Connor E, Scheidt-Nave C, McPhillips J,. Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. A population-based study. Diabetes Care 1993; 16: 1022-5. (Pubitemid 23184534)
21. Turner R, Stratton I, Horton V, et al., UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997; 350: 1288-93. (Pubitemid 28036638)
22. Muñiz García J, Pérez Castro T, Hervada Vidal X, et al., Enquisa sobre os hábitos alimentarios da poboaciõn adulta galega, 2007. Santiago de Compostela: Direcciõn Xeral de Saúde Pública. Consellería de Sanidade. Xunta de Galicia 2008.
23. Benito Lõpez P, García Mayor R, Puig Domingo M, et al., [Pathological characteristics of patients with diabetes mellitus type 2, in Spanish Primary Care. Rev Clin Esp 2004; 204: 18-24. (Pubitemid 38292420)
24. Franch Nadal J, Artola Menéndez S, Diez Espino J, et al., [The evolution of quality care indicators of patients with type 2 diabetes in the Spanish primary care (1996-2007). The RedGEDAPS quality of care program.. Med Clin (Barc) 2010; 135: 600-7.
25. Benito Lõpez P, García Mayor R, Puig Domingo M, et al., [Pathological characteristics of patients with diabetes mellitus type 2, in Spanish Primary Care. Rev Clin Esp 2004; 204: 18-24. (Pubitemid 38292420)
26. de la Calle H, Costa A, Díez-Espino J, et al., [Evaluation on the compliance of the metabolic control aims in outpatients with type 2 diabetes mellitus in Spain The TranSTAR study. Med Clin (Barc) 2003; 120: 446-50. (Pubitemid 36582172)
27. Arroyo J, Badía X, de la Calle H, et al., [Management of type 2 diabetic patients in primary care in Spain. Med Clin (Barc) 2005; 125: 166-72. (Pubitemid 41112939)
28. Grupo ELIPSE. Effectiveness of control of cardiovascular risk factors in type 2 diabetic population of Ciudad Real province. Rev Clin Esp 2005; 205: 218-22.
29. Agencia de Calidad del Ministerio de Sanidad y Consumo. Plan de Calidad del Sistema Nacional de Salud. 2007. Available from: http://www.msc.es/ organizacion/sns/planCalidadSNS/ (accessed 15 February 2008).
30. Ahmann A,. Guidelines and performance measures for diabetes. Am J Manag Care 2007; 13 (Suppl. 2): S41-6. (Pubitemid 46656061)
31. Parchman ML, Pugh JA, Romero RL, Bowers KW,. Competing demands or clinical inertia: the case of elevated glycosylated hemoglobin. Ann Fam Med 2007; 5: 196-201. (Pubitemid 46889995)
32. Wens J, Dirven K, Mathieu C, et al., Quality indicators for type-2 diabetes care in practice guidelines: an example from six European countries. Prim Care Diabetes 2007; 1: 17-23.
33. Gregg E, Karter A, Gerzoff R, et al., Characteristics of insured patients with persistent gaps in diabetes care services: the Translating Research into Action for Diabetes (TRIAD) study. Med Care 2010; 48: 31-7.
34. Mangione C, Gerzoff R, Williamson D, et al., The association between quality of care and the intensity of diabetes disease management programs. Ann Intern Med 2006; 145: 107-16. (Pubitemid 46780584)
35. Liebl A, Mata M, Eschwège E, Board O-A,. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002; 45: S23-8. (Pubitemid 34762211)
36. Piwernetz K, Home P, Snorgaard O, et al., Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee. Diabet Med 1993; 10: 371-7. (Pubitemid 23134749)
37. Pischon T,. Commentary: Use of the body mass index to assess the risk of health outcomes: time to say goodbye? Int J Epidemiol 2010; 39: 528-9.
38. Haslam DW, James WP,. Obesity. Lancet 2005; 366: 1197-209. (Pubitemid 41393598)
39. Hu FB,. Obesity and mortality: watch your waist, not just your weight. Arch Intern Med 2007; 167: 875-6. (Pubitemid 46762747)
40. Zhang X, Shu XO, Yang G, et al., Abdominal adiposity and mortality in Chinese women. Arch Intern Med 2007; 167: 886-92. (Pubitemid 46762750)
41. I. D. F. Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006; 23: 579-93.
42. Phillips L, Branch W, Cook C, et al., Clinical inertia. Ann Intern Med 2001; 135: 825-34. (Pubitemid 33051266)
43. Shah B, Hux J, Laupacis A, et al., Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005; 28: 600-6. (Pubitemid 40326231)
44. Grant R, Cagliero E, Dubey A, et al., Clinical inertia in the management of type 2 diabetes metabolic risk factors. Diabet Med 2004; 21: 150-5. (Pubitemid 38221814)
45. Davis D, O'Brien M, Freemantle N, et al., Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA 1999; 282: 867-74. (Pubitemid 29408939)
46. Martin S, Schramm W, Schneider B, et al., Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4). Exp Clin Endocrinol Diabetes 2007; 115: 495-501. (Pubitemid 350056761)